Comparison
Cagrilintide vs. Lixisenatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
1415456-99-3
320367-13-3
Molecular weight
4253.7 g/mol
4858.5 g/mol
Half-life
168 h
3 h
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2Mechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
5
of which in humans
3
5
Effects recorded
3
3
Open conflicts
0
1
Documented adverse events
1
1